Other phase I trials have indicated the safety and feasibility of visualizing tumors/quantifying PARP expression by means of [18F]F-PARPi in a range of tumor types (excluding breast cancer), for example, in patients with ovarian cancer [67] and head-and-neck cancer [68]. Here, PARP1 is linked to breast carcinoma.